ArticleHealth services research2010
The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study.
Article in Health services research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors.Pharmacoepidemiology and drug safety · 2026Article
- Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors.The Prostate · 2025Article
- Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients.Cancer epidemiology · 2025Article
- Disparities in the utilization of magnetic resonance imaging for prostate cancer detection: a population-based study.Journal of the National Cancer Institute · 2025Article
- Linking Medicare-Medicaid Claims for Patient-Centered Outcomes Research Among Dual-Eligible Beneficiaries.Medical care · 2023Article
- Survival of cancer survivors with a new pancreatic cancer diagnosis.Cancer medicine · 2023Article
- Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors.Journal of cancer survivorship : research and practice · 2022Article
- Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.Cancer medicine · 2021Article
- Survival of women diagnosed with breast cancer and who have survived a previous cancer.Breast cancer research and treatment · 2021Article
- Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.Cancer medicine · 2020Article
- Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.Journal of the National Cancer Institute · 2019Article
- Readmission Patterns After GI Cancer Hospitalizations: The Medical Versus Surgical Patient.Journal of oncology practice · 2018Article
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.British journal of cancer · 2017Article
- Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.Lung cancer (Amsterdam, Netherlands) · 2016Article
- Article
- Article
- Lasting Effects of the Breast and Cervical Cancer Early Detection Program on Breast Cancer Detection and Outcomes, Ohio, 2000-2009.Preventing chronic disease · 2015Article
- Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.Journal of the National Cancer Institute · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo compare the adequacy of the state buy-in variable (SBI) in the Medicare denominator file to identify dually eligible patients. DATA SOURCE/STUDY SETTINGS: We used linked Medicare and Medicaid data from Michigan and Ohio for elders diagnosed with incident breast, prostate, or colorectal cancer between 1996 and 2001. STUDY
designUsing the Medicaid enrollment file as the "gold standard," we assessed the number of duals from Medicare files in cross-sectional and longitudinal analyses. DATA COLLECTION/EXTRACTION
methodsData for the study population were linked with Medicare and Medicaid files using patient identifiers. PRINCIPAL
findingsSensitivity was low (74.2 percent, 95 percent confidence interval [CI]: 72.7, 75.6 and 80.8 percent, 79.7, 81.9, in Michigan and Ohio, respectively). PPV was above 95 percent in Michigan and 88.8 percent in Ohio. Both sensitivity and PPV varied between and within the states. Both in Michigan and in Ohio, we observed limited agreement on the length of enrollment in Medicaid between the two data sources.
conclusionsExcept to examine disparities by dual status at a very broad level, the SBI variable alone may be inadequate to identify duals. The findings call for improvements in Medicare and Medicaid information management systems and for uniformity in database linking strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.